Health & Biotech
PharmAust (ASX: PAA) has changed its name to Neurizon Therapeutics - NUZ (ASX: NUZ).
Below are the previous articles from PharmAust (ASX: PAA):
RELATED STOCKHEAD STORIES
Health & Biotech
PharmAust’s upcoming Phase 1 clinical trials receive major boost with the production of smaller tablets
Health & Biotech
PharmAust marches ahead to Phase 1 trials on COVID-19 and motor neurone disease
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
Health & Biotech
PharmAust expands studies in NZ, one step closer towards a Phase 3 trial for canine cancer
News
10 at 10: These ASX stocks are worth their weight in gold this morning
Health & Biotech
PharmAust makes important progress during quarter ahead of multiple clinical trials of lead drug, monepantel
Health & Biotech
PharmAust’s lead drug MPL step closer to COVID-19 and MND human clinical trials
Health & Biotech
PharmAust doubles life expectancy of pet dogs with cancer, a major step towards commercialisation
Health & Biotech
ASX Health Stocks: Proteomics jumps 13pc on diabetes test
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Merck’s COVID-19 breakthrough in the US gives boost to ASX- listed PharmAust
Health & Biotech
PharmAust reward loyal shareholders with attractively priced option offer
Health & Biotech
The ‘game changing’ waste-to-energy technology that could catapult PharmAust’s subsidiary Epichem into a $70b market
Health & Biotech
PharmAust’s wholly owned subsidiary Epichem pays off debt in full, ready to accelerate its growth phase
Health & Biotech
PharmAust’s subsidiary Epichem builds ‘world-first’ flow reactor to convert waste into fuel
Health & Biotech
